Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

By Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 254-260

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 726-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 541-548

John Wiley & Sons Inc

Access to resources Recommend Favorite